Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156261 | 0.92 | POLB (0.86) | POLBTSHRSMN1; SMN2LMNANOTUM | |
| SCHEMBL27353989 | 0.84 | TSHR (1.00) | POLBTSHRLMNAHTTNOTUM | |
| SCHEMBL21788621 | 0.84 | POLB (0.71) | POLBTSHRSMN1; SMN2LMNAHTT | |
| SCHEMBL698692 | 0.80 | POLB (0.67) | POLBTSHRSMN1; SMN2LMNAHTT | |
| SCHEMBL3092095 | 0.80 | POLB (0.65) | POLBTSHRSMN1; SMN2LMNANOTUM | |
| SCHEMBL4019697 | 0.79 | SMN1; SMN2 (0.79) | POLBTSHRSMN1; SMN2HTTNOTUM | |
| SCHEMBL4758824 | 0.78 | LMNA (1.00) | POLBTSHRSMN1; SMN2LMNAHTT | |
| SCHEMBL12685845 | 0.78 | TSHR (0.80) | POLBTSHRLMNAHTTNOTUM | |
| SCHEMBL29445653 | 0.78 | TSHR (0.80) | POLBTSHRLMNAHTTNOTUM | |
| SCHEMBL3330822 | 0.77 | POLB (0.63) | POLBTSHRSMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | POLB 2362/4885TSHR 2802/4885SMN1; SMN2 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.